Table 2. Endoscopy Score and Symptom Score Outcomesa.
| Variable | Mean (SD) | Comparison between groups, F statistic; η2 effect size (95% CI) | |
|---|---|---|---|
| Prednisone | Placebo | ||
| Lund-Kennedy score | |||
| Baseline | 3.8 (3.1) | 2.9 (2.5) | 1.23; 0.02 (0.00-0.50) |
| 1 wk | 5.3 (2.6) | 5.9 (3.0) | |
| 1 mo | 3.8 (2.6) | 3.5 (2.7) | |
| 3 mo | 2.4 (2.1) | 1.9 (2.1) | |
| 6 mo | 1.9 (1.8) | 1.3 (1.7) | |
| SNOT-22 total | |||
| Baseline | 43.8 (21.5) | 43 (22.4) | 1.71; 0.01 (0.00-0.05) |
| 1 wk | 39.7 (22.5) | 38.5 (21.2) | |
| 1 mo | 26.6 (20.8) | 28.6 (18.0) | |
| 3 mo | 28.3 (19.5) | 20.3 (15.2) | |
| 6 mo | 34.2 (20.6) | 25.2 (19.7) | |
| SNOT-22 rhinologic | |||
| Baseline | 10.9 (6.7) | 10.5 (6.5) | 0.99; 0.01 (0.00-0.04) |
| 1 wk | 7.8 (4.9) | 7.6 (5.3) | |
| 1 mo | 5.6 (4.2) | 6.6 (4.3) | |
| 3 mo | 6.2 (4.5) | 5.2 (4.6) | |
| 6 mo | 8.2 (6.8) | 6.2 (5.1) | |
| SNOT-22 extranasal rhinologic | |||
| Baseline | 7.3 (3.9) | 6.6 (4.0) | 0.41; 0.01 (0.00-0.02) |
| 1 wk | 6.4 (4.1) | 6.1 (3.8) | |
| 1 mo | 5.3 (4.2) | 4.6 (3.6) | |
| 3 mo | 4.8 (3.3) | 3.5 (2.5) | |
| 6 mo | 6.1 (3.4) | 4.3 (3.1) | |
| SNOT-22 ear-facial | |||
| Baseline | 10.0 (5.1) | 8.8 (5.5) | 0.89; 0.01 (0.00-0.04) |
| 1 wk | 8.7 (5.4) | 8.3 (5.2) | |
| 1 mo | 6.8 (5.5) | 6.8 (4.5) | |
| 3 mo | 6.1 (4.5) | 4.3 (3.9) | |
| 6 mo | 7.1 (4.7) | 4.4 (4.4) | |
| SNOT-22 sleep | |||
| Baseline | 12.4 (8.0) | 12.4 (7.1) | 1.02; 0.02 (0.00-0.04) |
| 1 wk | 11.9 (7.3) | 11.1 (7.7) | |
| 1 mo | 7.0 (6.9) | 8.2 (6.4) | |
| 3 mo | 8.0 (6.9) | 5.8 (5.7) | |
| 6 mo | 9.8 (7.3) | 8.1 (7.2) | |
| SNOT-22 psychologic | |||
| Baseline | 13.6 (10.3) | 15.9 (9.3) | 3.18; 0.05 (0.02-0.09) |
| 1 wk | 14.7 (9.4) | 13.8 (9.5) | |
| 1 mo | 7.9 (9.4) | 10.4 (7.9) | |
| 3 mo | 10.3 (10.6) | 7.2 (6.9) | |
| 6 mo | 11.5 (9.4) | 8.4 (8.6) | |
a
η2 value interpretation: 0.01, small effect size; 0.05, medium effect size; greater than 0.15, large effect size.